Publicaciones en colaboración con investigadores/as de University of Basel (45)

2024

  1. Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients

    ERJ Open Research, Vol. 10, Núm. 1

2023

  1. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry

    Multiple Sclerosis Journal, Vol. 29, Núm. 2, pp. 221-235

  2. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  3. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

  4. Impact of long-term exposure to ambient ozone on lung function over a course of 20 years (The ECRHS study): a prospective cohort study in adults

    The Lancet Regional Health - Europe, Vol. 34

  5. Long-term effect of asthma on the development of obesity among adults: an international cohort study, ECRHS

    Thorax, Vol. 78, Núm. 2, pp. 128-135

  6. Residential greenspace and lung function decline over 20 years in a prospective cohort: The ECRHS study

    Environment International, Vol. 178

  7. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

  8. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Association between use of enhanced recovery after surgery protocols and postoperative complications in colorectal surgery in Europe: The EuroPOWER international observational study

    Journal of Clinical Anesthesia, Vol. 80

  2. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

  4. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  5. Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis

    Psychological Medicine, Vol. 52, Núm. 8, pp. 1569-1577

  6. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

  7. The Impact of the COVID-19 Pandemic and Associated Control Measures on the Mental Health of the General Population

    Annals of Internal Medicine, Vol. 175, Núm. 11, pp. 1560-1571

2021

  1. Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice

    Schizophrenia Bulletin, Vol. 47, Núm. 2, pp. 284-297

  2. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  3. Sex-specific associations of basal steroid hormones and neuropeptides with Conduct Disorder and neuroendocrine mediation of environmental risk

    European Neuropsychopharmacology, Vol. 49, pp. 40-53

2020

  1. Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis

    Schizophrenia bulletin, Vol. 46, Núm. 4, pp. 823-833